Table 1 66 loci identified for asthma in meta-analysis of the UK Biobank and TAGC.

From: Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma

SNP	CHR	BP (hg19)	Nearest Gene(s)	EA/NEA	EAF	P_UKBB	P_TAGC	P_Meta-analysis	Direction	P-het
rs2230624^a,b	1p36.22	12,175,658	TNFRSF8	G/A	0.99	4.3E−12	0.95	2.4E−09	++	4.4E−04
rs11577318	1p36.11	26,601,570	CEP85	G/A	0.18	4.8E−05	5.8E−05	2.8E−08	++	0.18
rs2228552^b	1p35.2	32,165,495	COL16A1	T/G	0.63	3.4E−08	0.09	2.2E−08	++	0.16
rs4127124	1q32.1	206,624,362	SRGAP2	A/C	0.49	4.6E−09	0.10	4.5E−09	++	0.11
rs72787718	2p23.1	30,474,351	LBH	A/G	0.23	3.2E−08	0.04	7.7E−09	++	0.26
rs68110799	2p16.1	60,945,555	PAPOLG	A/G	0.26	8.9E−08	0.01	5.2E−09	++	0.50
rs35548551	2p13.2	72,039,714	DYSF	T/G	0.12	4.4E−07	1.1E−04	2.7E−10	++	0.48
rs6741949	2q24.2	162,910,223	DPP4	G/C	0.56	1.0E−08	0.03	1.5E−09	++	0.29
rs2595389	2q32.1	187,534,183	ITGAV	T/G	0.54	1.0E−05	8.9E−04	3.8E−08	++	0.57
rs13101202^c	3p25.2	12,699,361	RAF1	C/A	0.17	2.1E−09	0.81	1.5E−07	++	3.9E−03
rs2014490	3p24.3	16,972,211	PLCL2	G/A	0.65	9.2E−10	0.08	7.5E−10	++	0.10
rs2036226	3p24.3	23,597,986	UBE2E2	T/C	0.59	7.5E−08	4.7E−04	1.4E−10	++	0.82
rs73072483	3p21.2	50,771,624	DOCK3	G/A	0.87	1.4E−07	0.02	1.2E−08	++	0.47
rs9813229	3p14.3	56,741,585	ARHGEF3	A/G	0.62	1.4E−07	5.1E−03	2.6E−09	++	0.75
rs7372960	3p13	71,254,751	FOXP1	T/C	0.75	1.4E−07	0.05	3.5E−08	++	0.29
rs7622814	3q13.2	112,650,431	CD200R1	T/G	0.46	9.8E−09	9.5E−03	4.1E−10	++	0.46
rs9877891	3q13.33	119,260,866	CD80	C/T	0.18	2.7E−08	0.14	3.4E−08	++	0.11
rs17485347	3q26.2	169,127,519	MECOM	C/A	0.75	2.3E−06	2.0E−04	2.5E−09	++	0.45
rs6842889	4q31.21	145,479,880	LOC105377462	T/C	0.61	3.0E−06	3.1E−04	4.6E−09	++	0.49
rs11950815	5q31.1	130,955,487	RAPGEF6	G/A	0.63	8.6E−12	4.8E−04	2.0E−14	++	0.60
rs62379371^c	5q31.1	133,439,274	LOC105379185	G/A	0.95	6.5E−09	0.79	3.2E−07	++	0.01
rs11746314^a,b	5q33.3	156,752,957	CYFIP2	G/A	0.06	4.2E−11	7.7E−03	2.1E−12	++	0.26
rs3777755	6p24.1	12,159,699	HIVEP1	C/T	0.70	2.1E−07	7.0E−03	5.3E−09	++	0.72
rs13203384	6p22.3	19,341,301	MBOAT1	A/G	0.21	1.8E−06	5.8E−03	3.5E−08	++	0.92
rs952579	6p22.3	21,884,440	CASC15	A/G	0.14	2.4E−09	0.19	7.1E−09	++	0.05
rs766406^a	6p22.2	26,319,588	HIST1H4H/BTN3A2	T/G	0.65	7.8E−09	6.4E−07	5.8E−14	++	0.20
rs9394288	6p21.31	35,222,010	LOC101929285	T/C	0.20	2.3E−09	0.38	2.6E−08	++	0.02
rs11759732	6q21	109,370,006	SESN1	A/G	0.85	1.9E−08	3.4E−03	2.5E−10	++	0.70
rs4526212^a	6q23.3	135,804,631	AHI1	A/C	0.37	6.5E−11	7.2E−04	2.1E−13	++	0.64
rs13190880	6q24.2	143,222,770	HIVEP2	T/G	0.09	8.5E−08	5.1E−03	1.6E−09	++	0.72
rs431362	6q25.1	149,787,378	ZC3H12D	A/G	0.36	1.5E−08	2.8E−03	1.6E−10	++	0.72
rs4599658	6q25.2	155,074,505	SCAF8	G/T	0.47	1.8E−08	0.02	1.7E−09	++	0.37
rs73033536^a	7p22.2	3,149,883	LOC105375130	T/C	0.91	8.1E−11	1.6E−03	6.2E−13	++	0.52
rs7014953	8p23.1	8,168,413	SGK223	A/C	0.60	2.3E−07	9.9E−03	8.3E−09	++	0.65
rs34173062^b	8q24.3	145,158,607	MAF1/SHARPIN	A/G	0.07	1.3E−12	0.83	6.0E−10	++	5.2E−04
rs1537504^a,b	9q22.33	101,829,542	COL15A1	A/G	0.23	1.5E−07	1.1E−05	1.3E−11	++	0.29
rs4978607	9q32	117,508,437	TNFSF15	C/T	0.88	2.3E−08	0.19	4.5E−08	++	0.08
rs10986311	9q33.3	127,071,493	NEK6	C/T	0.37	2.7E−08	1.1E−05	2.1E−12	++	0.37
rs782134971	9q34.2	136,139,907	ABO	–/AAACTGCC	0.25	1.5E−05	3.7E−04	3.0E−08	++	0.41
rs9284092	10p11.23	30,801,718	MAP3K8	G/T	0.73	8.5E−06	3.3E−04	1.5E−08	++	0.43
rs12769745	10q11.21	43,749,700	RASGEF1A	A/G	0.28	1.5E−06	4.8E−03	2.4E−08	++	0.95
rs1134777	10q22.2	75,538,651	FUT11	C/G	0.73	2.3E−07	0.02	1.4E−08	++	0.54
rs714417	11p11.2	45,247,176	PRDM11	C/T	0.69	7.5E−08	1.9E−05	9.5E−12	++	0.37
rs12303699^a,b	12q22	94,582,336	PLXNC1	A/G	0.38	1.9E−09	9.7E−04	7.5E−12	++	0.79
rs61960013^a,c	13q14.11	44,490,181	LOC107984576	G/C	0.21	7.0E−09	0.96	6.1E−07	++	3.3E−03
rs3751289	14q23.1	61,983,943	PRKCH	G/A	0.22	9.8E−08	0.03	1.5E−08	++	0.35
rs10131197	14q32.12	93,015,394	RIN3	G/A	0.33	2.6E−10	0.02	4.6E−11	++	0.19
rs11259930^a	15q25.2	84,577,350	ADAMTSL3	A/G	0.47	8.5E−09	3.1E−05	1.4E−12	++	0.55
rs11645975	16p13.3	3,749,397	TRAP1	G/C	0.74	3.5E−05	1.7E−04	4.2E−08	++	0.28
rs223819	16q13	57,394,862	CCL22	T/C	0.91	2.3E−06	3.7E−03	3.0E−08	++	0.96
rs72842819	17p13.1	7,328,821	C17orf74/SPEM2	C/A	0.12	3.2E−09	0.06	1.6E−09	++	0.15
rs750065349	17p12	12,193,443	MAP2K4	GC/G	0.46	8.6E−10	0.38	1.1E−08	++	0.02
rs1991401^c	17q23.3	62,502,435	CEP95/DDX5	A/G	0.69	1.1E−08	0.50	1.6E−07	++	0.02
rs111365807	17q25.1	73,825,463	UNC13D	C/G	0.12	1.2E−07	0.06	3.5E−08	++	0.27
rs76848919^c	17q25.3	76,352,554	SOCS3	C/G	0.20	5.6E−09	0.55	2.7E−06	++	4.5E−04
rs12956924^c	18q21.1	46,451,146	SMAD7	A/G	0.32	3.7E−08	0.21	7.9E−08	++	0.08
rs117552144^b,c	19p13.3	3,136,091	GNA15	T/C	0.06	3.6E−11	0.26	3.5E−07	++	1.2E−05
rs10420217^c	19p13.3	4,355,871	MPND	C/T	0.28	2.0E−08	0.21	3.1E−05	++	7.6E−05
rs755023315	19p13.3	6,579,029	CD70	G/GC	0.29	2.7E−09	0.27	1.5E−08	++	0.03
rs34006614	19p13.11	16,442,782	KLF2	T/C	0.33	1.1E−07	0.02	1.0E−08	++	0.43
rs143432496	19q13.32	45,252,714	BCL3	A/ATAT	0.27	2.3E−11	0.10	4.8E−11	++	0.04
rs8103278^a,b	19q13.32	46,370,381	FOXA3	G/A	0.65	1.2E−08	5.1E−05	3.1E−12	++	0.59
rs11670020	19q13.41	52,314,161	FPR3/LOC105369197	G/A	0.14	1.7E−06	5.6E−03	3.2E−08	++	0.93
rs8125525	20q13.12	45,681,788	EYA2	C/T	0.74	1.7E−07	0.02	1.5E−08	++	0.46
rs1736147	21q21.1	16,813,053	LOC101927745	G/A	0.57	1.1E−07	6.1E−03	2.5E−09	++	0.70
rs34846236	21q22.2	41,049,344	PCP4	G/GC	0.48	5.3E−06	2.2E−03	4.3E−08	++	0.78

EA/NEA effect (asthma risk) allele/non-effect allele, EAF effect allele frequency (based on only the UK Biobank).
P-UKBB p-value from the GWAS in the UK Biobank as calculated by linear mixed models, P_TAGC imputed p-value from TAGC GWAS as calculated by SSimp software⁶³, P-het p-value for test of heterogeneity between the UK Biobank and TAGC.
^aIdentified by Johansson et al.¹² while this manuscript was under consideration.
^bIdentified by Olafsdottir et al.¹³ while this manuscript was under consideration.
^cLocus was genome-wide significant (P < 5.0E−08) in the UK Biobank alone.

Back to article page

Table 1 66 loci identified for asthma in meta-analysis of the UK Biobank and TAGC.

Search

Quick links